Under the MICROSC PE

A Deeper Look at Raleigh-Durham's Life Sciences Market




OVERVIEW

Vacancy within the Raleigh-Durham life sciences inventory continued to rise, hitting a new high-water mark of 32.3% in Q2 2025. The upward vacancy was driven by the recent delivery of buildings 100,000 sf or larger and policy changes to NIH funding. However, the market remains tight for smaller size ranges in R&D space within flex conversions and former office space. Nearly 2.3 msf of tenant requirements are currently active in the market, exceeding pre-pandemic figures though this total is down from the record high demand of mid-2022.



The delivery of new speculative product has driven vacancy upwards. Since the start of 2022, over **2.7 msf** of new life sciences product has delivered. By the end of Q3 2025, vacancy is expected to remain above **32.0%**.



Vacancy is **elevated** in high bay / cGMP properties—spaces which often cannot be demised—which target large-block space users searching for advanced manufacturing or distribution space. Meanwhile, R&D buildings maintain **lower** vacancy rates as their spaces are frequently demised into smaller suites.



KEY TERMINOLOGY

R&D: Optimized for scientific discovery. Often has a mix of office and "wet lab" space for advanced scientific research and development or experimentation. These properties are often multi-tenanted and multi-story structures.

cGMP: Product that abides by the Current Good Manufacturing Practice regulations enforced by the FDA. Space is designed to manufacture goods such as pharmaceutical products and medical devices.


Typically features upgraded power and infrastructure and contains loading docks.


Flex Conversion: Former flex industrial product that has been upgraded to accommodate both R&D and smaller scale cGMP users. Properties are multi-tenanted, single-story structure which often feature at least one rear-access loading dock per suite, utilize surface parking, and provide separately metered utilities. These types of properties are either in the cGMP building inventory or Single-Story R&D inventory depending on use.

High Bay: Property with a ceiling clear height of 32' or higher.




SUPPLY





VACANT SPACE BY BUILDING VINTAGE



Available spaces
100,000 sf or larger are
the primary driver of
the market's elevated
vacancy rate, making
up 51.2% of offerings on
the market. Conditions
remain tight among all
other size ranges.

Life sciences sublease
vacancy in Raleigh-Durham
has **increased** 230 bps over
the last year, while other
markets have recorded slight **decreases**. The only other
major market to record
a substantial uptick was
Boston, the industry's other
East Coast mainstay, where
sublease vacancy increased
90 bps in that time.

Buildings delivered in the last three years comprise 49.0% of all vacant space in the market. During this time, 18 buildings completed construction of which 12 remain fully vacant.

As interest rates have
risen, active tenant
pursuits have waned;
however, tour activity
has increased in 2025
and tenants continue to
explore options in the
market despite cuts to
funding.


Since the start of 2021, almost **2.8 msf** of new product has delivered and almost **610,000 sf** of space has been absorbed in that time.

In the last 12 months,
79.5% of all leases
signed were 20,000 sf
or smaller as tenants
continued to seek
space in smaller sized
configurations.

 \otimes

DEMAND


TENANTS IN THE MARKET AND INTEREST RATES




DELIVERIES AND DIRECT ABSORPTION



COUNT OF LEASING ACTIVITY BY DEAL SIZE - LAST 12 MONTHS




Raleigh-Durham remains a great place to invest. Leading global life sciences firms continue to contribute to the DNA of the market.



North Carolina universities have cultivated **131 life sciences** and related companies over the last decade which are operational today.

This emphasizes the commitment schools have to growing North Carolina as a life sciences hub, supporting startup culture, and creating and keeping talent in the state.



Source(s): Cushman & Wakefield Research, NC Biotech

Under the MICROSCOPE

A Deeper Look at Raleigh-Durham's Life Sciences Market

AUTHORS

MADELYN DAVIS

Senior Research Analyst +1 919 439 5148 madelyn.davis@cushwake.com

JP PRICE

Research Manager, Carolinas +1 704 335 4433 jp.price@cushwake.com

Better never settles



About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In 2024, the firm reported revenue of \$9.4 billion across its core service lines of Services, Leasing, Capital markets, and Valuation and other. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit www.cushmanwakefield.com.

©2025 Cushman & Wakefield. All right reserved. The information contained within this report is gathered from multiple sources belived to be reliable. The information may contain errors or omissions and is presented without any warranty or representations as to its accuracy.